Diabetic Retinopathy Market By Type (Proliferative DR, Non-Proliferative DR) By Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy) Is Expected To Reach USD 10.11 Billion By 2022: Grand View Research, Inc.
Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according to a new study by Grand View Research Inc. Diabetic retinopathy is considered as a serious sight threatening complication that results due to long term diabetes. The treatment line selection for diabetic retinopathy depends on the severity of the condition and may require intraocular injections, anti VEGF drugs, laser surgery or vitrectomy. Increasing incidences of diabetes, rising geriatric population base and the growing demand for early detection are some high impact rendering drivers of the diabetic retinopathy market. Furthermore, improving healthcare infrastructure, rising demand for cost-effective and safe treatment and rising focus of market players on emerging nations such as India and China are also anticipated to propel market growth. Presence of supportive government initiatives such as the Queen Elizabeth Diamond Jubilee Trust, which is taking initiatives for increasing patient awareness levels in order to promote regular retinal screening and early laser surgery to prevent permanent visual impairment and Ophthalmic Society of South Africa which works towards the improvement of reimbursement policies are anticipated to fuel the growth of the diabetic retinopathy market over the forecast period. View summary of this report analysis/diabetic-retinopathy-market
@
http://www.grandviewresearch.com/industry-